Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals

Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurshan, Ashwini, Snell, Luke B, Prior, Lucie, Tam, Jerry C H, Graham, Carl, Thangarajah, Rajeni, Edgeworth, Jonathan D, Nebbia, Gaia, Doores, Katie J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914479/
https://www.ncbi.nlm.nih.gov/pubmed/36844257
http://dx.doi.org/10.1093/oxfimm/iqac012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914479/
https://www.ncbi.nlm.nih.gov/pubmed/36844257
http://dx.doi.org/10.1093/oxfimm/iqac012

Ejemplares similares